Cancer clinical trials in the region Pays de la Loire

317 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Lymphoma #NCT06911502
B cell lymphoma Follicular lymphoma None > 60 ml/min 1 2 3 or more Chemotherapy Monoclonal antibodies
Centre Hospitalier Universitaire de Nantes (Nantes)
Celgene
Phase 3 Lung cancer #NCT05215340 #2023-507933-12-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK BRAF EGFR MET NTRK-1/2/3 RET ROS-1 Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC) Immunotherapy Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital Privé du Confluent - Vivalto Santé (Nantes)
Daiichi Sankyo
Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic None Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Hospitalier du Mans (Le Mans)
Summit Therapeutics
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer #NCT07087054 #2024-519875-24-00
Neuroendocrine tumor None
Centre Hospitalier Universitaire de Nantes (Nantes)
Crinetics Pharmaceuticals Inc.
Phase 3 Lung cancer #NCT04613596 #2023-508922-83-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive
Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Centre Hospitalier Universitaire de Nantes (Nantes), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Mirati Thérapeutique Inc.
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 Immunotherapy Chemotherapy
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1 Systemic Treatment-Naive Targeted therapy
Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Clinique Victor Hugo - Elsan (Le Mans), Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lymphoma #NCT05947851 #2022-501560-17-01
B cell lymphoma Lymphocytic lymphoma None Treated / Controled 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Merck Sharp & Dohme LLC
Phase 3 CLL & Richter's syndrome #NCT05947851 #2022-501560-17-01
CLL (Chronic Lymphocytic Leukemia) None Treated / Controled 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT06472245 #2023-509340-10-00
NSCLC (Non-Small Cell Lung Cancer) Metastatic 1 2 3 or more Immunotherapy
ALK EGFR ROS-1 Systemic Treatment-Naive
Centre Hospitalier de Cholet (Cholet), Centre Hospitalier Universitaire de Nantes (Nantes), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain), Centre Hospitalier du Mans (Le Mans), Centre Hospitalier Départemental de Vendée (La Roche-sur-Yon)
OSE Immunotherapeutics
Phase 3 Colon cancer #NCT05855200 #2023-503265-27-00
Adenocarcinoma Localized Locally Advanced MSI/dMMR None Systemic Treatment-Naive Systemic Treatment-Naive
MSS/pMMR
Centre Hospitalier Universitaire de Nantes (Nantes)
GlaxoSmithKline